Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Core Insights - Ocean Biomedical has developed a unique oncology platform targeting CHI3L1 to activate natural immune responses against various cancers, including lung cancer, glioblastoma, prostate cancer, melanoma, and breast cancer [1][2][4] Research and Development - New research published in the Journal of Immunology reveals how CHI3L1 inhibits the body's immune responses, particularly macrophage phagocytosis, by activating two key checkpoint pathways [1] - The research indicates that inhibiting CHI3L1 can enhance adaptive immune responses and reduce cancer growth in both standard and humanized mouse models [1][4] Patent and Therapeutic Potential - Ocean Biomedical has received patent allowances for multiple cancers, including prostate, colon, rectal, ovarian, kidney, breast, glioblastoma, melanoma, and lung cancer [2] - The company aims to advance towards IND-enabling studies to develop new cancer therapeutics based on the mechanisms discovered [4] Leadership and Vision - Dr. Jack A. Elias, a leading specialist in pulmonary care and co-founder of Ocean Biomedical, emphasizes the significance of controlling CHI3L1 to manage multiple anti-cancer pathways [3] - The company is focused on addressing unmet medical needs by accelerating the transition of scientific discoveries into therapeutics [6]